Literature DB >> 22223117

Histology classification challenges for the endoscopic treatment of early gastric cancer.

Christof Hottenrott.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22223117     DOI: 10.1007/s00464-011-2134-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


× No keyword cloud information.
  30 in total

1.  Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations.

Authors:  Dimitrios H Roukos; Niki J Agnanti; Evangelos Paraskevaidis; Angelos M Kappas
Journal:  Ann Surg Oncol       Date:  2002-12       Impact factor: 5.344

2.  Complete genome sequencing and network modeling to overcome trastuzumab resistance.

Authors:  Dimitrios H Roukos
Journal:  Pharmacogenomics       Date:  2010-08       Impact factor: 2.533

3.  Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends.

Authors:  Christos G Katsios; George Baltogiannis; Dimitrios H Roukos
Journal:  Expert Rev Anticancer Ther       Date:  2010-04       Impact factor: 4.512

Review 4.  Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.

Authors:  D H Roukos
Journal:  Pharmacogenomics J       Date:  2010-10-26       Impact factor: 3.550

5.  Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?

Authors:  Evangelos Briasoulis; Michael Fatouros; Dimitrios H Roukos
Journal:  Ann Surg Oncol       Date:  2007-07-26       Impact factor: 5.344

6.  Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer.

Authors:  Dimitrios H Roukos
Journal:  Ann Surg Oncol       Date:  2009-01-24       Impact factor: 5.344

7.  'Big' science: genome regulatory networks and novel molecular tools to improve health.

Authors:  Dimitrios H Roukos
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

8.  Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets.

Authors:  Dimitrios H Roukos
Journal:  Expert Rev Med Devices       Date:  2011-03       Impact factor: 3.166

9.  From tumor size and HER2 status to systems oncology for very early breast cancer treatment.

Authors:  Dimitrios H Roukos; Dimosthenis Ziogas
Journal:  Expert Rev Anticancer Ther       Date:  2010-02       Impact factor: 4.512

10.  Cancer genome explosion and systems biology: impact on surgical oncology?

Authors:  Dimitrios H Roukos
Journal:  Ann Surg Oncol       Date:  2011-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.